Hilton Baltimore Inner Harbor

Apr 05, 2027 8:00 AM - Apr 07, 2027 12:30 PM

401 W Pratt Street, Baltimore, MD 21201, USA

Global Pharmacovigilance and Risk Management Strategies Conference

REGISTER →

Early Bird Rate Ends



Print Agenda

Day 1 Apr 04, 2027

8:30 AM — 12:00 PM

Introduction to Benefit-Risk Management

1:00 PM — 4:30 PM

Global Convergence in Risk Management Guidance Driving New Innovation Opportunities

Day 2 Apr 05, 2027

7:30 AM — 5:00 PM

Conference Registration

7:30 AM — 8:30 AM

Networking Breakfast

8:30 AM — 8:45 AM

Welcome and Opening Remarks

Welcome and Opening Remarks
Track: General Session

Session Chair(s)



Sorcha McCrohan, MS

Sr. Scientific Project Manager
DIA, United States

Sorcha McCrohan is a Senior Scientific Project Manager for Global Science at DIA. In her current role, she focuses on content development and strategy for DIA's meetings to improve and facilitate innovation in clinical research, drug development, and the fields of devices and diagnostics. Before joining DIA, she conducted COVID-19 research in Chiapas, Mexico, and worked in marketing within Pfizer's Global Vaccines franchise. Sorcha holds a BA in Sociology from Mount Holyoke College and an MSc in Global Health, Disease Prevention & Control from Georgetown University.

8:45 AM — 9:30 AM

Session 1: Keynote Address

Session 1: Keynote Address

Track: General Session

Session Chair(s)



Representative Invited

United States

Speaker(s)



Speaker

Representative Invited

United States

9:30 AM — 10:15 AM

Networking Break

10:15 AM — 11:30 AM

Session 2: From Detection to Prediction. Rethinking Signal Management in the Age of AI


Signal management is entering its first real methodological shift in decades. The Innovative Health Initiative (IHI) has made this shift explicit. IHI Call 11, Topic 3, "AI-Powered Signal Detection in Pharmacovigilance," funds the development and validation of AI-based methods for early signal detection and risk prediction across heterogeneous data sources. The topic also calls for common data models, practical implementation guidance, and recommendations developed with regulators on how AI methods should be qualified for pharmacovigilance use. By April 2027 the selected consortium should be operational, which places DIA at an ideal point in the arc. The work, or at least clear plans, will be underway. This creates a genuine opportunity for a session to convene the people building these methods, the people who will have

to run them in a regulated safety system, and the regulators who will have to accept or reject their output. The functional focus is signal detection and risk prediction, positioned inside the wider question of safety governance and accountability.
Learning Objective : At the conclusion of this session, participants should be able to:

- Implement effective pharmacovigilance strategies for combination products, including medication error evaluation and incorporation of safety insights into device design and user instructions
- Differentiate risk escalation pathways and determine when safety concerns warrant device risk management actions versus formal

Track: General Session

Session Chair(s)



Tarek Hammad, MD, PhD, MS, MSc, FISPE

Vice President, Global Head of Medical Safety, Marketed Products and PDT, PSPV
Takeda Pharmaceuticals, United States

Dr. Tarek Hammad, VP & Head of Medical Safety for Marketed Products at Takeda Pharmaceuticals, is a renowned expert in drug safety, benefit-risk assessment, and pharmacoepidemiology. With extensive experience at major pharmaceutical companies like Sanofi and Merck, as well as a distinguished 13-year career at the US FDA, he has received numerous awards for his contributions. Dr. Hammad is a sought-after speaker, actively involved in industry initiatives and has held several academic appointments. He has authored over 80 peer-reviewed articles, book chapters, and letters to the editor, offering valuable insights in the field. Learn more at www.DrTarekHammad.com.

11:30 AM — 12:30 PM

Networking Luncheon

12:30 PM — 1:45 PM

Session 3: Navigate the GLP-1 Wave: PV Strategies for Consumer-Driven Use, Data, and Signals

GLP-1 therapies are reshaping pharmacovigilance as consumer demand, real-world use, digital discussion, and nontraditional access channels accelerate safety-data generation. This panel will examine how pharma safety and epidemiology/RWE teams can interpret signals across spontaneous reports, social media, patient communities, telehealth pathways, compounded or counterfeit products, and real-world evidence, while managing the operational challenges created by unprecedented reporting volumes. Speakers will discuss how regional regulatory expectations and available guidance may differ across markets, and share practical lessons for separating signal from noise, communicating risk, and applying the GLP-1 experience to future consumer-driven medicines.
Learning Objective : At the conclusion of this session, participants should be able to:

- Identify PV challenges created by consumer-driven GLP-1 use, reporting, and digital discussion

- Differentiate signal from noise across spontaneous reports, RWE, social media, and patient-generated data
- Apply practical considerations for risk communication and benefit-risk assessment in high-visibility GLP-1 settings

Track: General Session

Session Chair(s)



Vanessa Zapata

Associate Director, Global Clinical Safety & Pharmacovigilance Training Lead
Merck & Co., Inc., Canada

Vanessa Zapata is the Global Clinical Safety & Pharmacovigilance Training Lead at Merck & Co., Inc., where she leads PV training strategy, governance, and oversight. She serves as the business owner of Merck's global PV training, assigned annually to more than 120,000 employees and partners worldwide. With more than 25 years of pharmaceutical industry experience, including over a decade in PV, she has held positions of increasing responsibility across safety operations, compliance, and training. She is passionate about advancing patient safety through capability development and continuous learning.



Stephanie Millican, PhD, MSc

Deputy Director Benefit Risk Evaluation, Safety and Surveillance
MHRA, United Kingdom

Stephanie is the Deputy Director of Benefit Risk Evaluation II in the Safety and Surveillance group at the MHRA. Prior to her current role she held a variety of management and assessor positions in the Agency. She has a masters degree in Clinical Pharmacology and a PhD in Cell Biology. She joined the Agency following a career in academia and has now over 20 years experience in drug regulation with particular experience in post-authorisation procedures and pharmacovigilance.

1:45 PM — 2:30 PM

Networking Break

2:30 PM — 3:45 PM

Session 4: Clinical Trial Safety Data Evaluation, From Ongoing Monitoring to Risk Characterization

Clinical trial pharmacovigilance requires a structured and scientifically robust approach to safety monitoring, signal evaluation, and risk characterization throughout drug development. This session will provide practical perspectives on reviewing and interpreting clinical trial safety data across the development lifecycle, from ongoing blinded studies to post-unblinding benefit-risk assessments. Experts from industry and regulatory backgrounds will discuss best practices for aggregate safety review, evaluation of adverse events of special interest (AESIs), integration of laboratory and clinical data, effective data visualization, and approaches to defining adverse drug reactions (ADRs) and risks for Risk

Management Plans (RMPs). Through case examples and panel discussion, attendees will gain practical insights into modern approaches for translating clinical trial safety data into meaningful development and regulatory decisions.
Track: General Session

Session Chair(s)



Ranjeeta Sinvhal, MD

Executive Medical Director, Medical Safety
AbbVie, United States

Extensive experience in both post-marketing and pharmacovigilance in clinical trials for over 19 years. In-depth global filing experience as a safety lead for both small molecule and biologics. Co-chair of Cardiovascular Internal Safety Advisory Group at AbbVie. Member of DIA ASA Safety WG (workstream 3). Intimate knowledge of processes and regulations in ICSR, aggregate reporting and signal detection. Current knowledge of PV regulations including EU good pharmacovigilance practices. Comprehensive and current knowledge of Internal Medicine (current Board certification). Comprehensive knowledge of drug development process and conduct and reporting of post authorization studies.



Bethany Van Veen

CEO and Founder
Perspective Pharmacovigilance, United States

Bethany Van Veen has focused her entire career on pharmacovigilance (PV). Starting in the late 1990s, she began her PV career in drug safety operations at Elan Pharmaceuticals and continued to hold a variety of operational leadership roles within small and large organizations including J&J, Millennium and InterMune. She began her consulting career in 2013 and has advised over 125 companies. She values the importance of leveraging strong PV foundational skills to curate new ways of meeting global challenges. In 2017, she founded Perspective Pharmacovigilance, a think tank of PV experts. PPV's global staff of industry leaders, former PV department heads, and ex-regulators, design innovative solutions to a rapidly changing PV landscape.

3:50 PM — 5:05 PM

Session 5: Lessons from Post-Market Surveillance on How to Bridge Safety, Quality, and Device Risk

Combination drug-device products sit at the intersection of safety, quality, and device risk management, and post-market surveillance is where those disciplines either work together or work in silos. This session examines how safety and quality functions partner in practice: applying ICH Q9 principles to prospective Quality Risk Management, using adverse event data to inform continued process verification and signal detection, and supporting ad hoc or for-cause Health Risk Assessments and product recalls. Speakers will also address drug-device combination product surveillance specifically, including how post-market safety data shapes target product profiles and device development, how medication error data collection and term selection inform device design and user instructions, and how organizations decide between device risk management and Health Risk Assessment escalation pathways. The session will include case examples throughout and may reference the MedDRA Points to Consider Companion Document Section 5 on manufacturing and quality system issues, with perspectives from MedDRA MSSO, industry, and FDA.
Learning Objective :

At the conclusion of this session, participants should be able to:

- Use post-market safety data, including medication errors and adverse event trends, to guide device design.
- Decide when a safety issue needs device risk management versus a formal Health Risk Assessment.
- Apply ICH Q9 principles to signal detection and continued process verification.

Track: General Session

Session Chair(s)



Ranjeeta Sinvhal, MD

Executive Medical Director, Medical Safety
AbbVie, United States

Extensive experience in both post-marketing and pharmacovigilance in clinical trials for over 19 years. In-depth global filing experience as a safety lead for both small molecule and biologics. Co-chair of Cardiovascular Internal Safety Advisory Group at AbbVie. Member of DIA ASA Safety WG (workstream 3). Intimate knowledge of processes and regulations in ICSR, aggregate reporting and signal detection. Current knowledge of PV regulations including EU good pharmacovigilance practices. Comprehensive and current knowledge of Internal Medicine (current Board certification). Comprehensive knowledge of drug development process and conduct and reporting of post authorization studies.

5:05 PM — 6:05 PM

Networking Reception

Day 3 Apr 06, 2027

7:45 AM — 5:00 PM

Conference Registration

7:45 AM — 8:30 AM

Networking Breakfast

8:30 AM — 9:44 AM

Session 6: DIAmond Session: The Safety Pulse Continues. Executive Perspectives on PV Talent, Technology, and Regulation

This fireside chat brings back senior PV leadership to tackle the field's most pressing questions. Panelists will share how they are building resilient organizations, developing talent, applying AI across safety operations, and adapting to shifting expectations from FDA, EMA, and other regulators. Alongside these themes, panelists will share the career decisions and inflection points that shaped their own paths to safety leadership, and what it looks like for safety to operate as a strategic, value-adding function rather than a purely compliance-driven one.

Learning Objective :

At the conclusion of this session, participants should be able to:

- Identify current challenges and opportunities in global PV, pharmacoepidemiology, RWE, and clinical safety, including AI and evolving regulations.
- Contrast pharmacovigilance leadership approaches and structures across company sizes.
- Describe strategies for positioning safety as a value-adding function, not just compliance.

Track: General Session

Session Chair(s)



Jamie Wilkins, PharmD

Head, Risk Management Center of Excellence
AstraZeneca, United States

Jamie Wilkins, Pharm.D. is an experienced pharmacist and former regulator currently responsible for partnering with internal and external stakeholders on delivering innovative, strategic global safety and risk management excellence for Pfizer's drug and biologics portfolio. Prior to her role at Pfizer, Jamie served as the Deputy Director for the Division of Risk Management (DRM) at the US FDA. She is a two-time recipient of the FDA Francis O. Kelsey drug safety award, and has a deep passion for safety, and risk management science.

9:45 AM — 10:30 AM

Networking Breakfast

10:30 AM — 11:45 AM

Session 7: Predicting Safety Risk with AI, Digital Sensors, and Novel Data Sources

This session shifts from tactical, vendor-focused content to more strategic content on predictive safety, implementation, and automation. It focuses on the implementation of AI and machine learning (ML), including the use of digital sensors and other novel data sources, to identify, assess, and manage safety risks. The session also looks at how health authorities are increasingly evaluating the use of AI-driven approaches for signal detection, risk assessment, and safety decision making. Speakers will share core concepts, a practical example, and the FDA perspective, so participants can see both how these approaches work and how regulators view them.
Learning Objective :

- Define predictive safety and describe the data sources can be used to identify, assess, or manage safety risks
- Illustrate, using the example presented in this session, the key steps and considerations for implementing digital sensors for predicting patient safety risks
- Summarize the FDA perspective on how health authorities are evaluating AI-driven approaches for signal detection, risk assessment, and safety decision making

Track: General Session


Session Chair(s)



Balmeet Gurm, MD

Executive Director, Therapeutic Area Lead Cardiovascular and EBs, Patient Safety
Bristol Myers Squibb, United States

Balmeet Gurm is an accomplished physician with extensive experience in the pharmaceutical industry, specializing in oncology and cardiovascular therapeutic areas. Currently serving as Executive Director, Therapeutic Area Lead in Patient Safety at Bristol Myers Squibb (BMS), Balmeet brings a wealth of expertise in pharmacovigilance, risk management, and drug development. Balmeet transitioned to the pharmaceutical industry after practicing medicine for a few years and has held critical leadership roles in safety and pharmacovigilance across multiple organizations. Throughout a distinguished career, Balmeet has contributed significantly to advancing patient safety, regulatory compliance, and the successful development of innovative therapie



Tarek Hammad, MD, PhD, MS, MSc, FISPE

Vice President, Global Head of Medical Safety, Marketed Products and PDT, PSPV
Takeda Pharmaceuticals, United States

Dr. Tarek Hammad, VP & Head of Medical Safety for Marketed Products at Takeda Pharmaceuticals, is a renowned expert in drug safety, benefit-risk assessment, and pharmacoepidemiology. With extensive experience at major pharmaceutical companies like Sanofi and Merck, as well as a distinguished 13-year career at the US FDA, he has received numerous awards for his contributions. Dr. Hammad is a sought-after speaker, actively involved in industry initiatives and has held several academic appointments. He has authored over 80 peer-reviewed articles, book chapters, and letters to the editor, offering valuable insights in the field. Learn more at www.DrTarekHammad.com.

11:45 AM — 1:00 PM

Networking Luncheon and Roundtable Discussions

1:00 PM — 2:15 PM

Session 8: FDA's New IND Safety Reporting Guidance and What It Means for Sponsors Today

In December 2025, FDA finalized its guidance for industry regarding Sponsor responsibilities for safety reporting requirements and safety assessment for investigational new drug (IND) studies. This guidance provides an overview of the FDA's IND safety reporting requirements and includes, among other information, recommendations for the development of safety surveillance plans and considerations for aggregate data analyses as required by the IND safety reporting provisions (§§ 312.32(c)(1)(i)(C) or 312.32(c)(1)(iv)). In this session, representatives from FDA will provide an overview of the guidance, highlight key updates and discuss recommendations to help sponsors comply with these requirements. Additionally, representatives from Industry will provide real-world perspectives on translating the guidance into an operational framework for evaluating accumulating safety data across clinical development programs. Attendees will leave with strategies to develop process efficiencies and optimize overall compliance with IND safety reporting requirements.

Learning Objective :

At the conclusion of this session, participants should be able to:

- Understand FDA expedited safety reporting and updated aggregate analysis approaches
- Communicate serious safety risks while preserving trial integrity
- Identify key elements of an aggregate safety surveillance strategy
- Integrate blinded and unblinded aggregate analyses through independent review

Track: General Session

Session Chair(s)



Scott Janiczak, PharmD, MPH

Team Leader, Division of Pharmacovigilance-I, OSE, CDER
FDA, United States

LCDR Scott Janiczak, PharmD, MPH, BCPS, is a pharmacy officer in the U.S. Public Health Service, who serves as a Team Leader in the Division of Pharmacovigilance-I (DPV-I) within FDA's Center for Drug Evaluation and Research. In this role, he leads a multidisciplinary team reviewing post-market drug safety across therapeutic areas. Previously, he served as a safety evaluator in DPV-I (2020-2024) and regulatory affairs pharmacist in FDA's Office of Generic Drugs (2014-2020). LCDR Janiczak earned his PharmD from Midwestern University, completed a PGY-1 residency at Franciscan Health (Dyer, IN), and is board certified in Pharmacotherapy. He frequently presents on FDA drug safety initiatives at national conferences and academic institutions.

2:15 PM — 3:00 PM

Networking Breakfast

3:00 PM — 4:15 PM

Session 9: The Lean PV Playbook: Practical Approaches to Compliance, Outsourcing, and Growth For Emerging Companies

Small pharma and start-up PV teams must meet the same compliance expectations as larger organizations while operating with leaner resources and greater reliance on outsourcing. This interactive panel will bring together industry leaders and regulators to discuss practical approaches to maintaining oversight, preparing for inspections, and scaling PV systems without overbuilding. Through real-life scenarios, audience engagement, and lessons learned from organizations of different sizes, attendees will explore challenges in compliance, vendor governance, and growth. While focused on lean PV environments, the session will also provide valuable insights for larger companies seeking to simplify processes, optimize oversight, and enhance operational efficiency. Attendees will leave with practical, actionable strategies that can be applied across organizations at any stage of growth.
Learning Objective : At the conclusion of this session, participants should be able to:

- Identify key compliance and inspection readiness challenges in lean PV environments
- Evaluate practical approaches to vendor oversight and governance across different organizational models
- Apply lessons learned from real-world scenarios to scale PV systems while supporting business growth

Track: General Session

Session Chair(s)



Bethany Van Veen

CEO and Founder
Perspective Pharmacovigilance, United States

Bethany Van Veen has focused her entire career on pharmacovigilance (PV). Starting in the late 1990s, she began her PV career in drug safety operations at Elan Pharmaceuticals and continued to hold a variety of operational leadership roles within small and large organizations including J&J, Millennium and InterMune. She began her consulting career in 2013 and has advised over 125 companies. She values the importance of leveraging strong PV foundational skills to curate new ways of meeting global challenges. In 2017, she founded Perspective Pharmacovigilance, a think tank of PV experts. PPV's global staff of industry leaders, former PV department heads, and ex-regulators, design innovative solutions to a rapidly changing PV landscape.



Vanessa Zapata

Associate Director, Global Clinical Safety & Pharmacovigilance Training Lead
Merck & Co., Inc., Canada

Vanessa Zapata is the Global Clinical Safety & Pharmacovigilance Training Lead at Merck & Co., Inc., where she leads PV training strategy, governance, and oversight. She serves as the business owner of Merck's global PV training, assigned annually to more than 120,000 employees and partners worldwide. With more than 25 years of pharmaceutical industry experience, including over a decade in PV, she has held positions of increasing responsibility across safety operations, compliance, and training. She is passionate about advancing patient safety through capability development and continuous learning.

Day 4 Apr 07, 2027

8:00 AM — 12:45 PM

Conference Registration

8:00 AM — 8:30 AM

Networking Breakfast

8:30 AM — 9:45 AM

Session 10: Risk Minimization Innovations Across Regulatory, Digital and Value Generation

This session brings together several perspectives on potential developments in risk minimization. Initially, it will explore ongoing EMA thinking on the priority areas for risk minimization improvement and innovation and highlight recent regulatory updates. The session will then take an innovative turn and explore the potential for digital tools to better support risk minimization objectives, both in developed and developing economies including the potential for AI to enable greater outreach than has previously been possible. Finally, we will explore how the requirement for customer engagement, that is intrinsic to the role of risk minimization tools, can support asset value, not only relating to Safety requirements but potentially also to support Market Access, Reimbursement and other Medical objectives and thus to provide a channel to demonstrate a key aspect of Safety's value proposition to the wider organization.
Learning Objective :

- Describe key regulatory changes in Europe that affect risk minimization activities
- Develop risk minimization approaches that take advantage of digital functionality to achieve their objectives
- Confidently describe to cross-functional colleagues how innovative and integrated approaches to risk minimization tools and data collection could reduce costs of traditional post market studies and add asset value

Track: General Session

Session Chair(s)



Mark Perrott, PhD

Managing Partner
Axian Consulting Ltd., United Kingdom

Mark is a founder and managing partner at Axian Consulting, where he focuses on improving benefit-risk balance and outcomes for patients through improving communication and adding value using digital approaches. He has a >20 year pharma career which has included industry (Wellcome, GW, GSK and AZ) and consultancy roles (WCI, Foresight, PopeWoodhead, Huron and now is a founder and managing partner of Axian Consulting). He is now focusing on the opportunities presented by improved benefit-

risk management approaches to enhance risk management decision-making in development and on adding value to the interactions of industry and customers to maximise B-R balance and improve outcomes in REMS and aRMM programmes.

9:45 AM — 10:15 AM

Networking Break

10:15 AM — 11:15 AM

Session 11: From Qualitative to Quantitative, Practical Frameworks for Benefit-Risk Decisions

This session explores the evolution of structured benefit-risk assessment and how organizations are building practical frameworks to support transparent, consistent, science-driven decision making across the product lifecycle. Speakers will show how qualitative, semi-quantitative, and quantitative approaches come together to strengthen regulatory communications, risk management, and benefit-risk evaluations, using a real-world framework developed at BMS as a case study.
Track: General Session

Session Chair(s)



Michael Von Forstner, PhD, MPH, MSc

Managing Director, Head of Pharmacoepidemiology Practice
Mesa Laubela Consulting, Switzerland

Michael's main focus areas are the planning, development, implementation and evaluation of benefit-risk management solutions, as well as the optimization of processes around signal and benefit-risk management. He is engaged in developing and applying (benefit-) risk analysis and signal management methodologies in order to make RM planning more formally reproducible. Furthermore, he supports the development, implementation and evaluation of effectiveness of additional risk minimization and PV measures in the context of RMPs, as well as post-authorization studies to optimize the benefit-risk profiles of medicines.



Balmeet Gurm, MD

Executive Director, Therapeutic Area Lead Cardiovascular and EBs, Patient Safety
Bristol Myers Squibb, United States

Balmeet Gurm is an accomplished physician with extensive experience in the pharmaceutical industry, specializing in oncology and cardiovascular therapeutic areas. Currently serving as Executive Director, Therapeutic Area Lead in Patient Safety at Bristol Myers Squibb (BMS), Balmeet brings a wealth of expertise in pharmacovigilance, risk management, and drug development. Balmeet transitioned to the pharmaceutical industry after practicing medicine for a few years and has held critical leadership roles in safety

and pharmacovigilance across multiple organizations. Throughout a distinguished career, Balmeet has contributed significantly to advancing patient safety, regulatory compliance, and the successful development of innovative therapie

11:17 AM — 12:20 PM

Session 12: Working Across Systems: RMP, REMS, and Inspection Readiness for Global Sponsors

Most sponsors don't operate under a single regulatory system. They're managing EU Risk Management Plans and US Risk Evaluation and Mitigation Strategies at the same time, often for the same product, while inspectors from multiple agencies coordinate and share findings behind the scenes. This session walks through both systems side by side: what's changing in the EMA's GVP Modules V and VI and the RMP template format, and where REMS obligations stand on the US side. From there, the session turns to what happens when agencies actually show up. Inspectors and regulatory leads from multiple agencies join to discuss how sponsors navigate coordinated inspections in practice, what documentation burden looks like when findings cross borders, and how global companies stay ready for both systems at once.
Learning Objective :
At the conclusion of this session, participants should be able to:

- Identify key changes to GVP Modules V and VI and the revised RMP template.
- Compare REMS requirements with EU RMP obligations, noting differences and overlap.
- Describe how multi-agency inspection coordination works and how findings carry across agencies.
- Apply strategies for inspection readiness and documentation management across both systems.

Track: General Session

Session Chair(s)



Stephanie Millican, PhD, MSc

Deputy Director Benefit Risk Evaluation, Safety and Surveillance
MHRA, United Kingdom

Stephanie is the Deputy Director of Benefit Risk Evaluation II in the Safety and Surveillance group at the MHRA. Prior to her current role she held a variety of management and assessor positions in the Agency. She has a masters degree in Clinical Pharmacology and a PhD in Cell Biology. She joined the Agency following a career in academia and has now over 20 years experience in drug regulation with particular experience in post-authorisation procedures and pharmacovigilance.



Kal Elhoregy, RPh

Consulting
Consulting, United States

Kal Elhoregy is an accomplished healthcare industry executive with 25+ years' experience focused on implementation of Risk Minimization Programs, Quality Management Systems and Pharmacovigilance Quality and Compliance for companies within the pharmaceutical industry. As a strategist and accessible leader with experience in Pharmacovigilance and Quality Risk Management within the pharmaceutical industry, Kal has developed the infrastructure for managing all REMS programs and RMPs in

collaboration with multiple disciplines. Kal believes in leadership and teamwork and focuses on what is important to achieve successful results in ensuring patient safety and regulatory compliance.

12:20 PM — 12:30 PM

Closing Remarks

Closing Remarks
Track: General Session

Session Chair(s)



Sorcha McCrohan, MS

Sr. Scientific Project Manager
DIA, United States

Sorcha McCrohan is a Senior Scientific Project Manager for Global Science at DIA. In her current role, she focuses on content development and strategy for DIA's meetings to improve and facilitate innovation in clinical research, drug development, and the fields of devices and diagnostics. Before joining DIA, she conducted COVID-19 research in Chiapas, Mexico, and worked in marketing within Pfizer's Global Vaccines franchise. Sorcha holds a BA in Sociology from Mount Holyoke College and an MSc in Global Health, Disease Prevention & Control from Georgetown University.

12:30 PM — 12:30 PM

Conference Adjourns